紫杉醇脂质体与紫杉醇联合表阿霉素在乳腺癌新辅助化疗中的对照研究

目的　比较紫杉醇脂质体与普通紫杉醇联合表阿霉素两种方案在乳腺癌新辅助化疗中的临床疗效和安全性。方法　本试验采用开放式、随机、对照的方法进行研究。５６例需新辅助化疗的女性乳腺癌患者随机分为紫杉醇脂质体联合表阿霉素组（Ａ组）和普通紫杉醇联合表阿霉素组（Ｂ组）。Ａ组每周期予以紫杉醇脂质体１７５ｍｇ／ｍ^２，Ｂ组每周期予以紫杉醇１７５ｍｇ／ｍ^２，每周期两组表阿霉素均为７５ｍｇ／ｍ２。２１天为１周期，每周期评价毒性反应，２周期化疗后评价疗效。结果　入组病例中Ａ组完成２８例，Ｂ组完成２７例。Ａ组和Ｂ组的总有效率（ＣＲ＋ＰＲ）分别为５３.６％和４８.１％（Ｐ＞０.０５）。两组毒副反应中皮疹、皮肤潮红发生率具有明显差异，以Ａ组较低（Ｐ＜０.０５）；其他如血液学毒性、呕吐、腹泻及发热等基本一致（Ｐ＞０.０５）。结论　紫杉醇脂质体与普通紫杉醇联合表阿霉素方案在乳腺癌新辅助化疗中的疗效相当，但紫杉醇脂质体过敏反应发生率明显低于紫杉醇。

A controlled trial of neoadjuvant chemotherapy to patients with breast cancer treated with liposomal paclitaxel plus epirubicin and paclitaxel plus epirubicin

Objective To analyze the efficacy and safety of neoadjuvant chemotherapy to patients with breast cancer treated with liposomal paclitaxel plus epirubicin and paclitaxel plus epirubicin.Methods A open,randomized,controlled trial was performed in this study.A total of fifty-six female patients with breast cancer received neoadjuvant chemotherapy were randomly divided into group A and B.Patients in group A were treated with combination of liposomal paclitaxel(175mg/m2,d1) and epirubicin(75mg/m2,d1);patients in...